A Prospective, Multicenter, Open Label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus (RAD001) With Basiliximab, Corticosteroids and Lower Levels Versus Higher Levels of Tacrolimus in De Novo Renal Transplant Recipients.
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2011
At a glance
- Drugs Everolimus (Primary) ; Tacrolimus
- Indications Renal transplant rejection
- Focus Adverse reactions; Registrational
- Sponsors Novartis
- 14 May 2009 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History